Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...
Rutland Herald

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow ...
ascopubs.org

Consolidative camrelizumab following definitive concurrent chemoradiotherapy with involved-field irradiation in locally advanced esophageal squamous cell carcinoma: A single ...

A phase 1 study of fixed-dose regimens of serplulimab, an anti-PD-1 antibody, in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
ascopubs.org

Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study PD-1 immune checkpoint ...